Table 2.
Technique | System examined |
---|---|
Plate height method | Drug and solute binding with serum proteins (HSA); sugar-lectin interactions (Con A) |
Peak profiling | Drug, drug metabolite, and solute binding with serum proteins (AGP, HSA); drug binding with cyclodextrins; drug-receptor interactions (β2-AR) |
Peak decay | Drug binding with serum proteins (AGP, HSA); sugar-lectin interactions (Con A); antibody-antigen binding; aptamer-target interactions; interactions of immunoglobulins with protein A or protein G |
Split-peak method | Antibody-antigen binding; interactions of immunoglobulins with protein A or protein G |
Peak fitting in zonal elution | Sugar-lectin interactions (Con A); drug/inhibitor-receptor interactions (nAChR, β2-AR); drug binding with cyclodextrins; interactions of immunoglobulins with protein A; binding of novobiocin with heat shock protein; lysozyme binding with Cibacron Blue 3GA |
Peak fitting in frontal analysis | Sugar-lectin interactions (Con A); antibody-antigen binding |
Ultrafast affinity extraction | Drug and hormone binding with serum proteins (AGP, HSA, SHBG); |
AGP, α1-acid glycoprotein; β2-AR, beta2-adrenoceptor; Con A, concanavalin A; HSA, human serum albumin; nAChR, nicotinic acetylcholine receptor; SHBG, sex-hormone binding globulin.